Q-omics provides the consensus-scored KLHL8 profile across patient tissues and cancer cell-line models. KLHL8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLHL8 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, KLHL8 RNA expression shows 20,361 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where KLHL8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL8 survival associations across molecular data types. KLHL8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL8 RNA expression–survival associations across cancer types. High KLHL8 expression shows unfavorable associations in STAD and MESO, but favorable associations in KIRC, LUAD, HNSC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLHL8 RNA expression.
This table summarizes KLHL8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KLHL8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL8 shows lower tumor expression in THCA, KIRC, KIRP and LUAD and higher tumor expression in HNSC and STAD. The THCA box plot shows higher KLHL8 RNA expression in normal versus tumor tissue (log2 FC = −1.530, t-test p < 0.001).
This table shows molecular features associated with KLHL8 in patient tissues and cancer cell lines. In patient samples, KLHL8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
